Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse

Biochem Pharmacol. 2015 Mar 1;94(1):22-9. doi: 10.1016/j.bcp.2015.01.007. Epub 2015 Jan 23.

Abstract

Clinical and experimental studies suggest that pharmacological postconditioning with Cyclosporin A (CsA) reduces infarct size in cardiac ischemia and reperfusion. CsA interacts with Cyclophilin D (CypD) preventing opening of the mitochondrial permeability transition pore (mPTP). Tissue kallikrein (TK) and its products kinins are involved in cardioprotection in ischemia. CypD knockout mice are resistant to the cardioprotective effects of both CsA and kinins suggesting common mechanisms of action. Using TK gene knockout mice, we investigated whether the kallikrein-kinin system is involved in the cardioprotective effect of CsA. Homozygote and heterozygote TK deficient mice (TK(-/-), TK(+/-)) and wild type littermates (TK(+/+)) were subjected to cardiac ischemia-reperfusion with and without CsA postconditioning. CsA reduced infarct size in TK(+/+) mice but had no effect in TK(+/-) and TK(-/-) mice. Cardiac mitochondria isolated from TK(-/-) mice had indistinguishable basal oxidative phosphorylation and calcium retention capacity compared to TK(+/+) mice but were resistant to CsA inhibition of mPTP opening. TK activity was documented in mouse heart and rat cardiomyoblasts mitochondria. By proximity ligation assay TK was found in close proximity to the mitochondrial membrane proteins VDAC and Tom22, and CypD. Thus, partial or total deficiency in TK induces resistance to the infarct size reducing effect of CsA in cardiac ischemia in mice, suggesting that TK level is a critical factor for cardioprotection by CsA. TK is required for the mitochondrial action of CsA and may interact with CypD. Genetic variability in TK activity has been documented in man and may influence the cardioprotective effect of CsA.

Keywords: Cardiac ischemia–reperfusion; Cyclosporin A; Mitochondria; Tissue kallikrein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiotonic Agents / pharmacology*
  • Cyclophilins / genetics
  • Cyclophilins / metabolism
  • Cyclosporine / pharmacology*
  • Gene Expression
  • Heterozygote
  • Homozygote
  • Ischemic Postconditioning*
  • Male
  • Mice
  • Mice, Knockout
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / metabolism
  • Mitochondrial Membrane Transport Proteins / genetics
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Permeability Transition Pore
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / genetics
  • Myocardial Ischemia / metabolism
  • Myocardial Ischemia / pathology
  • Myocardium / metabolism
  • Myocardium / pathology
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Oxidative Phosphorylation
  • Peptidyl-Prolyl Isomerase F
  • Rats
  • Signal Transduction
  • Tissue Kallikreins / deficiency
  • Tissue Kallikreins / genetics*
  • Voltage-Dependent Anion Channel 1 / genetics
  • Voltage-Dependent Anion Channel 1 / metabolism

Substances

  • Cardiotonic Agents
  • Peptidyl-Prolyl Isomerase F
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • PPIF protein, mouse
  • Vdac1 protein, mouse
  • Cyclosporine
  • Voltage-Dependent Anion Channel 1
  • Tissue Kallikreins
  • Cyclophilins